PAKIANATHAN DEEPIKA — SEC insider filings
SEC reporting owner CIK 1270734. 25 insider filings on record with FilingPulse; latest filed 2026-09-24.
Transaction summary — filings shown
Covers all 25 filings on record, filed 2021-04-29 to 2026-09-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 21 legs across 5 filings — 2,489,583 shares, $5,613,538 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 48.
- Largest priced transaction: sale of 322,825 shares @ $6.50 ($2,099,428) in Karyopharm Therapeutics Inc., filed 2022-06-10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | Director | 9 | — | 18 legs · 2,263,006 sh · $5,100,518 | 6 |
| Mereo BioPharma Group plc (MREO) | Director | 4 | — | 1 leg · 105,244 sh · $466,210 | 15 |
| Calithera Biosciences, Inc. (CALA) | Director | 3 | — | 2 legs · 121,333 sh · $46,810 | 2 |
| Theravance Biopharma, Inc. (TBPH) | Director | 7 | — | — | 21 |
| PARDES BIOSCIENCES, INC. (PRDS) | Director | 2 | — | — | 4 |
Insider filings — PAKIANATHAN DEEPIKA
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-24 | 4 | Theravance Biopharma, Inc. (TBPH) | Disposition to issuer (D): 58,065 · Disposition to issuer (D): 6,009 · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 6,000 (derivative) · Disposition to issuer (D): 28,000 (derivative) · Disposition to issuer (D): 22,044 (derivative) · +3 more | EDGAR |
| 2026-06-16 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 6,009 @ $0 · Grant/award (A): 13,398 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-02-27 | 4 | Mereo BioPharma Group plc (MREO) | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 4,600 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,649 @ $0 · Grant/award (A): 24,258 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Mereo BioPharma Group plc (MREO) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2024-08-23 | 4 | Mereo BioPharma Group plc (MREO) | Option exercise (M): 1,825 @ $3 · Option exercise (M): 6,492 @ $1.84 · Option exercise (M): 12,418 @ $2.72 · Option exercise (M): 38,953 @ $1.31 · Option exercise (M): 43,485 @ $0.94 · Option exercise (M): 2,071 @ $3.87 · +7 more | EDGAR |
| 2024-06-07 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Sale (S): 463,518 @ $0.96 · Sale (S): 4,526 @ $0.96 · Sale (S): 117,307 @ $0.98 · Sale (S): 1,145 @ $0.98 · Sale (S): 229,308 @ $0.95 · Sale (S): 2,240 @ $0.95 | EDGAR |
| 2024-06-04 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Sale (S): 202,418 @ $0.95 · Sale (S): 1,976 @ $0.95 · Sale (S): 357,256 @ $1.00 · Sale (S): 3,488 @ $1.00 · Sale (S): 337,742 @ $0.95 · Sale (S): 3,298 @ $0.95 | EDGAR |
| 2024-05-30 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 69,000 (derivative) @ $0 | EDGAR |
| 2024-05-10 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 10,537 @ $0 · Grant/award (A): 23,576 (derivative) @ $0 | EDGAR |
| 2024-02-09 | 4 | Mereo BioPharma Group plc (MREO) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2023-05-04 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 9,132 @ $0 · Grant/award (A): 22,044 (derivative) @ $0 | EDGAR |
| 2023-01-31 | 4 | Calithera Biosciences, Inc. (CALA) | Sale (S): 120,161 @ $0.39 · Sale (S): 1,172 @ $0.39 | EDGAR |
| 2022-06-10 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Sale (S): 322,825 @ $6.50 · Sale (S): 3,152 @ $6.50 · Sale (S): 209,455 @ $6.18 · Sale (S): 2,045 @ $6.18 · Sale (S): 1,294 @ $6.00 · Sale (S): 13 @ $6.00 | EDGAR |
| 2022-06-03 | 4 | Calithera Biosciences, Inc. (CALA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 23,900 (derivative) @ $0 | EDGAR |
| 2022-04-28 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 9,852 @ $0 · Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2021-12-30 | 4/A | PARDES BIOSCIENCES, INC. (PRDS) | Conversion (C): 30,000 @ $0 · Conversion (C): 30,000 (derivative) @ $0 | EDGAR |
| 2021-12-28 | 4 | PARDES BIOSCIENCES, INC. (PRDS) | Conversion (C): 52,500 @ $0 · Conversion (C): 52,500 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | Calithera Biosciences, Inc. (CALA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2021-05-21 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 23,900 (derivative) @ $0 | EDGAR |
| 2021-04-29 | 4 | Theravance Biopharma, Inc. (TBPH) | Grant/award (A): 9,828 @ $0 · Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-04-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1270734 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs